Scipharm Sarl v. Asstt. Controller Of Patents And Designs

Every year, millions of dollars and years of research go into developing treatments for diseases that affect millions of lives. But what happens when the gatekeeper of innovation—the patent office—says no? For Scipharm Sarl, a pharmaceutical company that believed it had developed a novel composition for treating cystic fibrosis, that 'no' became the beginning of a high-stakes legal battle. This case is a powerful reminder for founders and innovators in the life sciences space: securing a patent is not just about having a great idea, it's about surviving the gauntlet of examination and, when necessary, fighting back in court.

Scipharm Sarl, a pharmaceutical entity, filed a patent application titled 'Novel Composition for the Treatment of Cystic Fibrosis'—a title that signals both scientific ambition and a commitment to addressing a serious genetic disorder. Cystic fibrosis is a life-threatening condition, and any novel therapeutic composition targeting it carries enormous commercial and humanitarian weight. However, the Assistant Controller of Patents and Designs reviewed the application and ultimately refused to grant the patent. This refusal set the stage for Scipharm Sarl to challenge the decision. The matter, originally routed through the Intellectual Property Appellate Board (IPAB), was transferred to the Delhi High Court as part of the broader restructuring of IP tribunals in India.

On one side stands Scipharm Sarl, the appellant, arguing that its composition represents a genuine, novel advancement in the treatment of cystic fibrosis and deserves the protection of a patent. On the other side is the Assistant Controller of Patents and Designs, representing the patent office's position that the application did not meet the requirements for patentability. The legal friction here is classic: an innovator believes its work is groundbreaking enough to warrant exclusive rights, while the patent examiner has concluded otherwise. The transfer of the case from the IPAB to the Delhi High Court added another layer of procedural complexity, as the matter had to find its footing in a new judicial forum.

On 20 October 2022, the Delhi High Court took up the matter and issued notice to the parties. The court directed both Scipharm Sarl and the patent office authorities to file written submissions, setting the stage for a thorough examination of the refusal. As of the latest update, the case remains pending, with the written submissions expected to shape the court's eventual ruling on whether the 'Novel Composition for the Treatment of Cystic Fibrosis' will be granted patent protection.

For founders, biotech entrepreneurs, and IP professionals, this case underscores a critical lesson: a patent refusal is not the end of the road—it is often the beginning of a fight that must be waged with diligence and preparation. When the patent office says no, the quality of your written submissions, the strength of your novelty arguments, and your readiness to engage with the legal process can make or break your appeal. More broadly, this case highlights the importance of building a robust patent strategy from day one—anticipating examiner objections, documenting inventive steps meticulously, and being prepared to escalate when necessary. In the world of pharmaceutical innovation, where the stakes are measured in both lives and livelihoods, persistence in protecting your IP is not optional; it is essential.